glp 1 drugs for type 2 diabetes Clinical Focus on GLP-1 Agonists in Mellitus Can Type 1 and Type

During COVID, doctors and researchers observed "cytokine storms" in patients that's when the immune system becomes overactive, ultimately causing severe inflammation

Public Plan Spending Context The Globe and Mail reports that public plans spent $794 million on Ozempic in 2024, and if plans cover Mounjaro, it could cost them an estimated $1.97 billion over three years, about $820 million more than the plans currently spend on comparable drugs over a similar period [Source: theglobeandmail.com/business/economy/article-canada-drug-agency-mounjaro-recommendation-type-2-diabetes/]

Reduced gastric emptying and delayed intestinal motility have been reported in the case of long-acting GLP-1R agonists(48) as well as GLP-1R GIPR dual agonist Tirzepatide(49).GIPR is present in key feeding centers at the hypothalamus and intracerebroventricular administration of acyl GIP causes acute neural activation in the feeding centers that includes the arcuate nucleus, dorsomedial hypothalamic nucleus, ventromedial nucleus of the hypothalamus, and lateral hypothalamus (50)

Bertin, E., Arner, P., Bolinder, J

These binding affinities compare similarly to native GIP for its receptor but are approximately 5-fold lower when compared to native GLP-1 for its receptor 44